- Solve real problems with our hands-on interface
- Progress from basic puts and calls to advanced strategies
Interactive Options Course
“More book recommendations please” was the feedback from one Blog reader after post #11 where we profiled James Lovelock’s Novacene and its implications for the AI thematic. Longevity is another topic on which we have written extensively. The Why We Die by Nobel Prize winner Venki Ramakrishnan provides many useful perspectives on the subject.
At its core, Ramakrishnan’s thesis is both sobering and strangely reassuring: ageing is not a problem to be ‘solved’ in the conventional sense, but rather a by-product of how evolution has optimised life. Biology prioritises reproduction and early survival, not long-term maintenance. Over time, the body accumulates damage at the molecular and cellular level, and the systems responsible for repair and renewal themselves degrade. In other words, death is not a failure of the system, but an inevitable feature of it. This stands in contrast to some of the more bullish narratives around radical life extension that have recently grown in prominence.
Yet this does not imply that nothing can be done. Quite the opposite. Ramakrishnan highlights that while there may be no single silver bullet, incremental advances in understanding biology are already delivering meaningful improvements in healthspan rather than lifespan. This aligns with our thesis that longevity is less about living forever and more about living better for longer.
At the same time, the book injects a note of caution into some of the more speculative corners of the theme. The complexity of human biology should not be underestimated. Interventions that target one pathway may create unintended consequences elsewhere. Moreover, there are important societal questions: what would materially longer lives mean for intergenerational equity, resource allocation and inequality? Technological improvement does not exist in a vacuum.
Ultimately, Why We Die reinforces the idea that the longevity theme is both powerful and nuanced. Progress is real, but likely to be evolutionary rather than revolutionary. As with many of the other themes we track, the winners may emerge not from those promising the most dramatic breakthroughs, but from those building the infrastructure – diagnostics, therapeutics and data – that enable better outcomes. Death, it seems, remains undefeated for now. But the journey towards delaying it – and improving the quality of life along the way – remains one of the most compelling frontiers of innovation.
—
Originally Posted May 2026
Please note, the Future Trends Blog will return in the second week of June once the Heptagon team is back from its annual firmwide offsite.
The above is provided for information purposes only and does not constitute investment advice or a recommendation to buy or sell any security. Any forward looking statements are based on assumptions that may change. The views expressed are solely those of the author at the time of writing. This article should not be relied upon for investment decisions. Past performance does not predict future returns, the value of investments and income from them can fall as well as rise
The document is provided for information purposes only and does not constitute investment advice or any recommendation to buy, or sell or otherwise transact in any investments. The document is not intended to be construed as investment research. The contents of this document are based upon sources of information which Heptagon Capital believes to be reliable. However, except to the extent required by applicable law or regulations, no guarantee, warranty or representation (express or implied) is given as to the accuracy or completeness of this document or its contents and, Heptagon Capital, its affiliate companies and its members, officers, employees, agents and advisors do not accept any liability or responsibility in respect of the information or any views expressed herein. Opinions expressed whether in general or in both on the performance of individual investments and in a wider economic context represent the views of the contributor at the time of preparation. Where this document provides forward-looking statements which are based on relevant reports, current opinions, expectations and projections, actual results could differ materially from those anticipated in such statements. All opinions and estimates included in the document are subject to change without notice and Heptagon Capital is under no obligation to update or revise information contained in the document. Furthermore, Heptagon Capital disclaims any liability for any loss, damage, costs or expenses (including direct, indirect, special and consequential) howsoever arising which any person may suffer or incur as a result of viewing or utilising any information included in this document.
The document is protected by copyright. The use of any trademarks and logos displayed in the document without Heptagon Capital’s prior written consent is strictly prohibited. Information in the document must not be published or redistributed without Heptagon Capital’s prior written consent.
Heptagon Capital LLP, 63 Brook Street, Mayfair, London W1K 4HS
tel +44 20 7070 1800
fax +44 20 7070 1881
email london@heptagon-capital.com
Partnership No: OC307355 Registered in England and Wales Authorised & Regulated by the Financial Conduct Authority
Information posted on IBKR Campus that is provided by third-parties does NOT constitute a recommendation that you should contract for the services of that third party. Third-party participants who contribute to IBKR Campus are independent of Interactive Brokers and Interactive Brokers does not make any representations or warranties concerning the services offered, their past or future performance, or the accuracy of the information provided by the third party. Past performance is no guarantee of future results.
This material is from Heptagon Capital and is being posted with its permission. The views expressed in this material are solely those of the author and/or Heptagon Capital and Interactive Brokers is not endorsing or recommending any investment or trading discussed in the material. This material is not and should not be construed as an offer to buy or sell any security. It should not be construed as research or investment advice or a recommendation to buy, sell or hold any security or commodity. This material does not and is not intended to take into account the particular financial conditions, investment objectives or requirements of individual customers. Before acting on this material, you should consider whether it is suitable for your particular circumstances and, as necessary, seek professional advice.
Related Articles
Join The Conversation
For specific platform feedback and suggestions, please submit it directly to our team using these instructions.
If you have an account-specific question or concern, please reach out to Client Services.
We encourage you to look through our FAQs before posting. Your question may already be covered!